Get the Stockscreener App
2.30
7.63%
-0.19
Biorestorative Therapies Inc stock is traded at $2.30, with a volume of 90,889.
It is down -7.63% in the last 24 hours and up +27.78% over the past month.
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.
See More
Previous Close:
$2.49
Open:
$2.49
24h Volume:
90,889
Relative Volume:
1.30
Market Cap:
$15.71M
Revenue:
$149.50K
Net Income/Loss:
$-6.96M
P/E Ratio:
-1.6912
EPS:
-1.36
Net Cash Flow:
$-6.37M
1W Performance:
-3.36%
1M Performance:
+27.78%
6M Performance:
+74.24%
1Y Performance:
+61.97%
1-Day Range:
$2.27
$2.495
1-Week Range:
$2.26
$2.5107
52-Week Range:
$1.03
$2.55
Biorestorative Therapies Inc Stock (BRTX) Company Profile
Name
Biorestorative Therapies Inc
Sector
Industry
Phone
(631) 760-8100
Address
40 MARCUS DRIVE, MELVILLE
Compare BRTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BRTX
Biorestorative Therapies Inc
|
2.31 | 15.71M | 149.50K | -6.96M | -6.37M | -1.36 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.14 | 122.13B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
715.03 | 78.30B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
651.43 | 39.73B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
276.81 | 35.50B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.12 | 28.47B | 3.30B | -501.07M | 1.03B | -2.1146 |
Biorestorative Therapies Inc Stock (BRTX) Latest News
BioRestorative Therapies, Inc.'s (NASDAQ:BRTX) Shift From Loss To Profit - Yahoo Finance
BioRestorative Therapies (OTCMKTS:BRTXQ) Trading Down 0.9%Here's Why - MarketBeat
BioRestorative Therapies Presents Promising Data at Orthopaedic Research Society (ORS) 2024 Annual Meeting - ACCESS Newswire
With BioRestorative Therapies Up 18%, Insider Buyers Count Their Returns - Simply Wall St
BioRestorative Therapies (OTCMKTS:BRTXQ) Stock Price Up 0.7%Here's Why - MarketBeat
BioRestorative Therapies (OTCMKTS:BRTXQ) Shares Up 0.7% – Here’s What Happened - Defense World
BioRestorative Therapies, Inc. announced that it has received $1 million in funding - Marketscreener.com
Pleasing Signs As A Number Of Insiders Buy BioRestorative Therapies Stock - Yahoo Finance
BioRestorative Therapies (OTCMKTS:BRTX) Share Price Passes Above Fifty Day Moving Average – Here’s What Happened - Defense World
BioRestorative Therapies (OTCMKTS:BRTXQ) Hits New 12-Month HighTime to Buy? - MarketBeat
BioRestorative Therapies Announces Notice of Allowance of - GlobeNewswire
BioRestorative Therapies Secures Key European Patent for Revolutionary Obesity Treatment Technology - StockTitan
BioRestorative Ends Q3 In ‘Strong’ Financial Position, Reports Positive Data For Its Phase 2 BRTX-100 Chronic Back Pain Trial - Nasdaq
BioRestorative Ends Q3 In 'Strong' Financial Position, Reports Positive Data For Its Phase 2 BRTX-100 Chronic Back Pain TrialEli Lilly (NYSE:LLY), BioRestorative Therapies (NASDAQ:BRTX) - Benzinga
Presenting Encouraging Data, Acquiring Licenses, Issuing Patents And More – BioRestorative's Inroads Bringing Its Stem Cell Therapies To Market - Nasdaq
BioRestorative Therapies Provides Business Update and Financial Results for Q3 2024 - Defense World
Analyzing American Caresource (OTCMKTS:GNOW) & BioRestorative Therapies (NASDAQ:BRTX) - Defense World
BioRestorative Therapies, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
BioRestorative Therapies, Inc. (NASDAQ:BRTX) Q3 2024 Earnings Call Transcript - Insider Monkey
BioRestorative Therapies Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
BioRestorative Therapies earnings beat by $0.31, revenue fell short of estimates - Investing.com Canada
BioRestorative Therapies Q3 2024 Financial Update - TipRanks
BioRestorative Therapies Lower Back Candidate Shows Decrease In Pain, Increased Function - Benzinga
BioRestorative Therapies Reports Positive Preliminary Phase 2 BRTX-100 Clinical Data - OrthoSpineNews
BioRestorative's BRTX-100 Shows 100% Success Rate in Early Back Pain Trial Data | BRTX Stock News - StockTitan
BioRestorative Therapies Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire
BioRestorative Therapies Enters at-the-Market Offering Agreement with Rodman & Renshaw LLC - Defense World
Roth Capital Issues Optimistic Outlook for BRTX Earnings - Defense World
BioRestorative Therapies to Announce Phase 2 Trial Data - TipRanks
Research Analysts Offer Predictions for BRTX Q1 Earnings - Defense World
BioRestorative Therapies inks new equity deal - Investing.com
BioRestorative Therapies inks new equity deal By Investing.com - Investing.com UK
BRTXBioRestorative Therapies, Inc. Latest Stock News & Market Updates - StockTitan
BioRestorative Therapies to Present New Clinical Data at the ORS PSRS 7th International Spine Research Symposium - The Manila Times
BioRestorative to Present Expanded BRTX-100 Phase 2 Trial Data for Chronic Back Pain Treatment | BRTX Stock News - StockTitan
Broadrick Dale reduces stake in BioRestorative Therapies, Inc. with $1,756 sale - Investing.com
BioRestorative Therapies Receives Expanded Tissue License from New York State Department of Health - GlobeNewswire
BioRestorative Therapies (OTCMKTS:BRTXQ) Reaches New 12-Month HighShould You Buy? - MarketBeat
BioRestorative Therapies Receives Patent Allowance for ThermoStem® Metabolic Disease Program - GlobeNewswire
BioRestorative Therapies (OTCMKTS:BRTXQ) Sets New 1-Year HighHere's Why - MarketBeat
BioRestorative Therapies to Participate in Upcoming UBS and Maxim Group Investor Events - GlobeNewswire
BioRestorative Therapies (OTCMKTS:BRTXQ) Sets New 52-Week HighWhat's Next? - MarketBeat
BioRestorative Therapies (OTCMKTS:BRTX) Stock Price Passes Below 50-Day Moving Average – Here’s Why - Defense World
BioRestorative Therapies to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference - GlobeNewswire
BioRestorative Therapies (OTCMKTS:BRTXQ) Sets New 1-Year High at $1.79 - Defense World
BioRestorative Therapies, Inc. (NASDAQ:BRTX) Short Interest Update - Defense World
Biorestorative Therapies Inc Stock (BRTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Biorestorative Therapies Inc Stock (BRTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Silva Francisco | VP of Research and Development |
Apr 09 '24 |
Buy |
1.25 |
6,600 |
8,250 |
155,759 |
| Silva Francisco | VP of Research and Development |
Apr 08 '24 |
Buy |
1.16 |
1,708 |
1,979 |
149,159 |
| Broadrick Dale | 10% Owner |
Feb 09 '24 |
Buy |
1.32 |
86,041 |
113,574 |
477,972 |
| Broadrick Dale | 10% Owner |
Feb 08 '24 |
Buy |
1.25 |
73,959 |
92,449 |
391,931 |
| Broadrick Dale | 10% Owner |
Feb 08 '24 |
Buy |
1.34 |
83,626 |
112,059 |
447,045 |
0.59%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):